<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01940965</url>
  </required_header>
  <id_info>
    <org_study_id>LTS12809</org_study_id>
    <secondary_id>U1111-1129-8754</secondary_id>
    <nct_id>NCT01940965</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes</brief_title>
  <official_title>An Open-Label, Multicenter 52-Week Study Assessing the Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      The primary objective of this study is to assess the overall safety of lixisenatide once
      daily treatment in combination with background oral anti-diabetic treatment over 52 weeks in
      patients with type 2 diabetes in Japan.

      Secondary Objective:

      To assess the effects of lixisenatide in combination with background oral antidiabetic drug
      (OAD) on:

        -  HbA1c;

        -  Fasting plasma glucose;

        -  Body weight.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      54 weeks +/-11 days
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety over 52 weeks assessed by treatment emergent adverse event (TEAE), vital signs, 12-lead electrocardiogram (ECG), and laboratory data</measure>
    <time_frame>52 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in HbA1c</measure>
    <time_frame>From baseline to weeks 24 and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in fasting plasma glucose</measure>
    <time_frame>From baseline to weeks 24 and 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in body weight</measure>
    <time_frame>From baseline to weeks 24 and 52</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">294</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Lixisenatide + Biguanide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>52-week treatment with Lixisenatide in combination with biguanide (usual maintenance dose in the label)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lixisenatide + TZD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>52-week treatment with lixisenatide in combination with TZD (usual maintenance dose in the label)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lixisenatide + alpha-GI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>52-week treatment with Lixisenatide in combination with alpha-GI (usual maintenance dose in the label)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lixisenatide + Glinide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>52-week treatment with Lixisenatide in combination with glinide (usual maintenance dose in the label)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lixisenatide AVE0010</intervention_name>
    <description>Pharmaceutical form:solution Route of administration: Subcutaneous injection</description>
    <arm_group_label>Lixisenatide + TZD</arm_group_label>
    <arm_group_label>Lixisenatide + Glinide</arm_group_label>
    <arm_group_label>Lixisenatide + alpha-GI</arm_group_label>
    <arm_group_label>Lixisenatide + Biguanide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>biguanide</intervention_name>
    <description>Pharmaceutical form:tablet Route of administration: oral</description>
    <arm_group_label>Lixisenatide + Biguanide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TZD</intervention_name>
    <description>Pharmaceutical form:tablet Route of administration: oral</description>
    <arm_group_label>Lixisenatide + TZD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alpha-GI</intervention_name>
    <description>Pharmaceutical form:tablet Route of administration: oral</description>
    <arm_group_label>Lixisenatide + alpha-GI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glinide</intervention_name>
    <description>Pharmaceutical form:tablet Route of administration: oral</description>
    <arm_group_label>Lixisenatide + Glinide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Patients with type 2 diabetes mellitus diagnosed at least 1 year before the screening
             visit

          -  Patient treated for at least 3 months prior to screening visit with one of following
             OADs at a stable dose of at least usual maintenance dose as described in the label

               -  a biguanide (metformin hydrochloride);

               -  a thiazolidinedione (TZD) (pioglitazone hydrochloride);

               -  an alpha-glucosidase inhibitor (alpha-GI) (acarbose, voglibose or miglitol);

               -  or a glinide (nateglinide, repaglinide or mitiglinide);

          -  Signed written informed consent

        Exclusion criteria:

          -  At screening HbA1c &lt;7% or &gt;9.5%;

          -  At screening: fasting plasma glucose &gt;250 mg/dL (&gt;13.9 mmol/L);

          -  Use of any glucose-lowering agent(s) other than the authorized patient's background
             treatment defined in I02 (as given in inclusion critieria) within 3 months prior to
             screening;

          -  Type 1 diabetes mellitus;

          -  Women of childbearing potential with no effective contraceptive method;

          -  Pregnancy or lactation;

          -  Laboratory findings at the time of screening:

               -  Amylase and/or lipase &gt;3 times the upper limit of the normal laboratory range
                  (ULN);

               -  ALT &gt;3 ULN;

          -  Any contra-indication to the patient's background oral anti-diabetic treatment;

          -  History of acute or chronic pancreatitis, pancreatectomy, stomach/gastric surgery,
             inflammatory bowel disease;

          -  Personal or immediate family history of medullary thyroid cancer (MTC) or genetic
             conditions that predispose to MTC (eg, multiple endocrine neoplasia syndromes);

          -  Any previous treatment with lixisenatide (eg, participation in a previous study with
             lixisenatide) or any other GLP1 receptor agonist.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 392335</name>
      <address>
        <city>Adachi-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392325</name>
      <address>
        <city>Chiba-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392328</name>
      <address>
        <city>Chiyoda-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392326</name>
      <address>
        <city>Chuo-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392327</name>
      <address>
        <city>Chuo-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392310</name>
      <address>
        <city>Chuoh-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392336</name>
      <address>
        <city>Kagoshima-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392314</name>
      <address>
        <city>Kamakura-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392334</name>
      <address>
        <city>Kashiwara-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392304</name>
      <address>
        <city>Kawagoe-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392306</name>
      <address>
        <city>Kawaguchi-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392307</name>
      <address>
        <city>Kisarazu-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392301</name>
      <address>
        <city>Koriyama-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392312</name>
      <address>
        <city>Mitaka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392302</name>
      <address>
        <city>Mito-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392324</name>
      <address>
        <city>Mito-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392331</name>
      <address>
        <city>Nagoya-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392332</name>
      <address>
        <city>Nagoya-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392329</name>
      <address>
        <city>Ohta-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392322</name>
      <address>
        <city>Okawa-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392333</name>
      <address>
        <city>Osaka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392330</name>
      <address>
        <city>Sagamihara-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392320</name>
      <address>
        <city>Saijo-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392303</name>
      <address>
        <city>Sakado-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392311</name>
      <address>
        <city>Shinjuku-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392316</name>
      <address>
        <city>Shizuoka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392319</name>
      <address>
        <city>Suita-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2013</study_first_submitted>
  <study_first_submitted_qc>September 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2013</study_first_posted>
  <last_update_submitted>August 3, 2015</last_update_submitted>
  <last_update_submitted_qc>August 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lixisenatide</mesh_term>
    <mesh_term>Hypoglycemic Agents</mesh_term>
    <mesh_term>Biguanides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

